About: Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People's Republic of China. Its lead product candidate is the ADG126, a masked fully-human anti-CTLA-4 mAb which is in phase 1b/2 clinical development for the treatment of cancer. The company also develops ADG116, a fully human anti-CTLA-4 antibody generated using NEObody technology, which is in phase 1b/2 clinical trials to treat advanced/metastatic solid tumors; ADG206, which is in phase 1 clinical development to treat advanced metastatic solid tumors; ADG104, anti-PD-L1 monoclonal antibody which is in phase 2 clinical development; and ADG125, a novel anti-CSF-1R mAb which is in Phase 2 clinical development. In addition, it is developing ADG138, a HER2xCD3 POWERbody which is in pre clinical trial to treat low expressing tumors, as well as resistant/refractory tumors; ADG152, a CD20xCD3 POWERbody which is in preclincal trial to treat off-tumor toxicities; ADG153, a masked anti-CD47 IgG1 SAFEbody, wihx is in preclinical trial for the treatment of hematologic and solid tumor; and CD28 T-cell engagers, an anti-CD28 bispecific POWERbody TCEs to treat solid tumors. Adagene Inc. was incorporated in 2011 and is headquartered in Suzhou, China.
Sector: Healthcare
Industry: Biotechnology
Latest price: $2.68 (+0.37%)
ADAG NASDAQ Adagene Inc
Adagene Inc share price
Atividade de preço de ADAG
Último preço
$ 2,680
Variação (24h)
0,01 USD (0,37%)
Volume
171.72K
Volume (média 4 sem.)
-
Abertura
$ 2,65
Variação do dia
$ 2,60 - $ 2,72
Fechamento anterior
$ 2,67
Último negócio
29 Oct, 8:14 pm GMT+0
Atrasado
29 Oct, 8:14 pm GMT+0
ADAG price performance
Atrasado
29 Oct, 8:14 pm GMT+0
quote.marketSignals